WO2001034776A1 - Hematopoietic differentiation of human embryonic stem cells - Google Patents
Hematopoietic differentiation of human embryonic stem cells Download PDFInfo
- Publication number
- WO2001034776A1 WO2001034776A1 PCT/US2000/023469 US0023469W WO0134776A1 WO 2001034776 A1 WO2001034776 A1 WO 2001034776A1 US 0023469 W US0023469 W US 0023469W WO 0134776 A1 WO0134776 A1 WO 0134776A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- human
- hematopoietic
- cell
- hematopoietic cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1394—Bone marrow stromal cells; whole marrow
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Definitions
- the present invention relates to the use of human embryonic stem cells to create blood-related cells, and the use of those blood-related cells for various purposes.
- the cell lines are maintained long term without differentiation into specific cell types.
- the cell lines are subsequently injected into immunodeficient mice, they form teratomas demonstrating differentiation into multiple tissue types.
- hematopoietic stem cells When ES cells are used to produce desired cells, it is often preferable to optimize differentiation towards specific cell types. In the case of hematopoietic cells it is desirable that this result in hematopoietic cells that can be isolated and used to form multiple hematopoietic lineages. These cells may include, but not be limited to, hematopoietic stem cells.
- Hematopoietic stem cell populations have been isolated directly from bone marrow. See C. Baum et al . 89 PNAS USA 2804-2808 (1992) . However, this relies on a supply of bone marrow to obtain the cells.
- WO 98/07841 there was discussed techniques of deriving embryonic stem cells that are MHC compatible with a selected donor (e.g. transplanting a donor nucleus into an enucleated oocyte, followed by derivation of the stem cells therefrom) .
- the application suggested that the resulting cells could be used to obtain MHC compatible hematopoietic stem cells for use in medical treatments requiring bone marrow transplantation.
- pancreatic islets which are MHC compatible to the diseased individual
- pancreatic islets which are MHC compatible to the diseased individual
- the present invention provides a method for obtaining human hematopoietic cells.
- One exposes a human embryonic stem cell culture to mammalian hematopoietic stromal cells so as to thereby create human hematopoietic cells.
- At least some of the human hematopoietic cells that are so created are CD34 + and/or are capable of forming hematopoietic cell colony forming units in methylcellulose culture.
- CD34 is a standard marker for hematopoietic stem cells, as described in C. Baum et al. 89 PNAS USA 2804- 2808 (1992) and S. Morrison et al . , 11 Ann . Rev. Cell Dev. Biol., 35-71 (1995).
- the property of capability of forming a colony forming unit is indicative that the cells have the desired characteristics to form more differentiated hematopoietic lineages.
- the stromal cells are preferably derived from bone marrow cells or embryonic yolk sac cells.
- Murine stromal cells may be used for this purpose.
- primate stromal and other mammalian stromal cells should be suitable as well.
- the invention provides a human hematopoietic cell which was derived from a human embryonic stem cell culture in vitro, and is capable of forming hematopoietic cell colony forming units in methylcellulose culture.
- derived is intended to mean obtained directly or indirectly (e.g. through one or more intermediates or passages) .
- the invention provides a method of transplanting human cellular material into a human recipient host.
- One obtains human hematopoietic cells which have been derived in . vitro from an embryonic stem cell culture.
- One obtains a selected human cellular material other than hematopoietic cells, the selected non-hematopoietic material having major histoco patibility complex compatibility to the hematopoietic cells.
- One transplants both the hematopoietic cells and selected human non-hematopoietic cellular material into the human host.
- the pancreatic islets can be obtained directly from a donor whose cells were used to create the embryonic stem cell culture.
- a single embryonic stem cell culture can be differentiated along two different paths. In one process the above technique can be used to create hematopoietic stem cells.
- These cells should develop into multiple hematopoietic lineages when transplanted into appropriate hosts. These lineages should include lymphocytes which would be tolerant of other cells derived from the same parental embryonic stem cells. In another process the stem cells would be directed towards pancreatic islets.
- the same human whose genetic material was used to create the embryonic stem cell can be a donor for the oligodendrocytes.
- the same embryonic stem cell culture can be differentiated along two separate paths to provide the two transplantable materials.
- the immune and autoimmune rejection problems should be reduced by this technique.
- the recipient's original bone marrow can be totally or partially inactivated by radiation or chemical means before the transplantation. Thereafter, it is replaced at least in part by the transplanted hematopoietic cells.
- the elimination/reduction of the original bone marrow reduces the body' s ability to create an autoimmune response.
- the matching of the MHC of the replacement bone marrow and the second transplantable material insures that the second material won' t be rejected by the transplanted bone marrow.
- co-transplantation of hematopoietic cells and other tissue can be done to promote acceptance of the second tissue (e.g. heart muscle plus hematopoietic cells for treating heart disease; hepatocytes plus hematopoietic cells for treating liver disease) .
- the second tissue e.g. heart muscle plus hematopoietic cells for treating heart disease; hepatocytes plus hematopoietic cells for treating liver disease.
- the present invention should be suitable to obtain a wide variety of hematopoietic cells of interest, such as erythroid cells, granulocyte cells, macrophages, lymphocyte precursors, monocytes, B cells, T cells, and the like.
- colonies of differentiated ES cells develop into hematopoietic colonies when harvested, separated into single cells, and plated into appropriate cultures.
- colony-forming cells which proliferate into colony- forming units (including colony forming unit-erythroid (CFU-E) , blast forming unit-eythroid (BFU-E) , colony forming unit-macrophage (CFU-M) , colony forming unit- granulocyte/macrophage (CFU-GM) and colony forming unit- high proliferative potential (CFU-HPP) ) .
- the identification of colony forming cells indicates the differentiation of embryonic stem cells into hematopoietic cells capable of expanding into defined hematopoietic lineages under defined conditions.
- the objects of the present invention therefore include providing:
- the dish was first coated with 0.1% gelatin solution (Sigma) for one or more days in a 37°C/5% CO, incubator. After the one or more days, the gelatin solution was removed and the wells of the plate were next coated with irradiated mouse embryonic fibroblast (MEF) cells.
- MEF cells were derived from day 12-13 mouse embryos in medium consisting of DMEM (GibcoBRL) supplemented with 10% fetal bovine serum (Hyclone or Harlan) , 2 mM 1-glutamine (GibcoBRL), and 100 units/ml. Penicillin, 100 mg/ml streptomycin (Sigma).
- the MEF cells were irradiated with 5500 cGy from a cesium source prior to plating in the wells.
- the MEFs were added at a density of 5 x 10 4 cells/ml, 2.5 ml/well.
- the plate coated with MEFs was then placed in 37°C/5% C0 2 incubator for one or more days until addition of ES cells .
- ES cells were passed onto new MEFs at approximately 5-8 day intervals. The time depends on cell density and morphologic appearance of differentiation. For passage, the medium in a well of ES cells was removed and 1-2 ml of medium containing 1 mg/ml collagenase IV in DMEM (GibcoBRL) was added. The plate was then placed at 37°C/5% C0 2 for 5-20 minutes until the colonies of ES cells began to round up.
- the well was then scraped with a 5 ml pipette to detach the ES cells from the plate.
- the contents of the harvested well were placed in a 15 ml conical tube (Fisher) and spun in a centrifuge at 1000 rpm for 5 minutes. The medium was removed and 10 ml of fresh medium was added.
- This ES cell medium consists of F12/DMEM (GibcoBRL) ) supplemented with 20% serum replacement medium (GibcoBRL) , 8 ng/ml of bFGF (GibcoBRL) , 1% non- essential amino acid solution (GibcoBRL) , 1 mM 1- glutamine (GibcoBRL), and 0.1M ⁇ -mercaptoethanol .
- the cells were again spun (5 min/1000 rpm), medium removed and resuspended at a concentration of 2.5 ml of medium for each (typically 15 ml medium for plating into 6 new wells, this would be a 1:6 passage).
- the cells were then pipetted into the wells of a plate that had been previously coated with MEFs as described above. The cells were evenly distributed into each well and the plate was placed in an incubator at 37°C/5% C0 2 .
- the ES cells were harvested as above. The cells were then plated in 6 well plates coated with a mammalian stromal cell. In one experiment we used C166 cells that were previously irradiated with 2500 cGy. The C166 cells were originally obtained from the yolk sac of mice at embryonic day 12 and were religiously provided by Dr. Robert Auerbach (UW-Madison) .
- S17 cells were used. They were originally obtained from mouse bone marrow, and were felicitly provided by Dr. Kenneth Dorshkind (then at UC- Riverside, now at UCLA) .
- the C166 or S17 cells were plated at a density of 1 x 10 " cells/ml, 2.5 ml/well.
- the ES cells plated onto either S17 of C166 cells were then allowed to grow in a medium consisting of DMEM (GibcoBRL) supplemented with 20% fetal bovine serum (Hyclone), 1% nonessential amino acid solution, 0.1M ⁇ -mercaptoethanol , and 1 mM 1- glutamine. This medium was replaced in each well at 24-72 hour intervals with fresh medium. In selecting an appropriate medium, one merely needs to provide conventional conditions for cell growth, albeit supplemented with the specified stromal cells.
- the ES cells After 3-7 days from plating onto S17 or C166 cells, the ES cells began to visually appear differentiated in that they did not have the same uniform appearance as the undifferentiated ES cells maintained on MEF feeder cells. The colonies of ES cells began to form multiple different cell types. Some of these colonies had regions that appeared to consist of cells with a cobblestone morphology indicative of colonies of early hematopoietic progenitor cells.
- CFCs hematopoietic colony forming cells
- the ES cells were allowed to differentiate on either C166 or S17 cells for 2-3 weeks, maintained as described above. After this time the medium was removed. 2.5 ml of calcium and magnesium free phosphate buffered saline (PBS) was added for 2-5 minutes, removed, and 1.5 ml . of trypsin ( 0.125% ) -EDTA (ImM) medium was added.
- the cells were then placed at 37°C/5% C0 2 for 10 minutes. After this time, the colonies began to disassociate. The cells were further disassociated by pipetting and scraping the wells. The cells were placed in a 15 ml. conical, spun 5 min/1000 rpm, medium removed and 10 ml fresh medium (DMEM + 10 % FBS + l-glutamine+ pen/strep) was added, and spun again. The cells were then suspended in 5 ml medium and passaged through a 100 mM nytex filter to remove clumps of cells.
- DMEM + 10 % FBS + l-glutamine+ pen/strep 10 ml fresh medium
- the filter was washed with an additional 5 ml medium.
- the disassociated/filtered cells were then counted on a hemacytometer and 1 x 10 6 (usually, but not always this many cells) cells were placed in a new 15 ml conical. These cells were then spun, medium removed and 5 ml medium consisting of IMDM (GibcoBRL) supplemented with 2% fetal bovine serum (Hyclone) was added. Cells were spun, medium removed and 250 ul medium (IMDM + 2% FBS) was added.
- IMDM GibcoBRL
- Hyclone 2% fetal bovine serum
- Methocult GF+ H4435 medium (StemCell Technologies) .
- This medium consists of 1.0% methylcellulose, supplemented with 30% FBS, 20 ng/ml IL-3, 20 ng/ml IL-6, 50 ng/ml stem cell factor, 3 units/ml erythropoietin, 20 ng/ml GM-CSF, 20 ng/ml G-CSF, 2 mM 1-glutamine, 0. ImM b-mercaptoethanol , 1% bovine serum albumin.
- the cells in methylcellulose were then vortexed vigorously and then 1.1 ml of the mixture was plated onto a P35 plastic dish (Stem Cell Technologies), spread evenly on the dish and placed at 37°C/5% C0 2 .
- Duplicate plates of each sample were typically plated with 4 x 10 5 cells/plate. After 14-21 days, the plates were analyzed under a microscope for the presence of hematopoietic colonies. The colonies were identified by comparison to a colony atlas (StemCell Technologies) or the book: Culture of Hematopoietic Cells, RI Freshney, IB Pragnell, MG Freshney, eds . , Wiley-Liss, Inc. 1994.
- Colonies were identified as one of the following: colony forming unit-erythroid (CFU-E) , blast forming unit- eythroid (BFU-E) , colony forming unit-macrophage (CFU-M) , colony forming unit-granulocyte/macrophage (CFU-GM) or colony forming unit-high proliferative potential (CFU- HPP) .
- CFU-E colony forming unit-erythroid
- BFU-E blast forming unit- eythroid
- CFU-M colony forming unit-macrophage
- CFU-GM colony forming unit-granulocyte/macrophage
- CFU- HPP colony forming unit-high proliferative potential
- ES cells differentiated on S17 cells or C166 cells as described above for 14-21 days were harvested with trypsin/EDTA as described above and passed through a 100 mM nytex filter. The filtered cells were counted on a hemacytometer, then aliquotted into 15 X 75 plastic tubes (Fisher) at approximately 1 x 10 5 cells/tube. The cells were then spun, medium removed and 2-3 ml of FACS medium was added. (FACS medium is PBS with 0.5% BSA (Sigma), 0.1% sodium azide (Sigma)).
- the cells were again spun and medium removed. Next an antibody directly linked to a fluorescent marker (FITC or PE) was added to the wells at a concentration as recommended by the supplier. Cells have been analyzed with the following antibodies: CD34-FITC ( Immunotech) , CD45-PE (Pharmingen) . IgGl-FITC and IgGl-PE were used as isotype controls for non-specific staining of the cells. Cells were incubated with the appropriate antibody for approximately 30 min on ice, washed 1-2 times with 2-3 ml FACS medium and resuspended in approximately 0.5 ml FACS medium.
- FITC or PE fluorescent marker
- the antibody labeled cells were then analyzed using a FACScan (Becton Dickinson) as per manufacturers recommendations. The presence of dead cells was determined by addition of propidium iodide (1 mg/ml solution, 5 ul added per tube) or 7-AAD (Calbiochem) (0.2 mg/ml ,5 ul/tube) .
- the software for analysis was either PC Lysis or Cellquest.
- the following experimental techniques were used to analyze antigen expression by immunohistochemistry (IHC).
- IHC immunohistochemistry
- differentiated ES cells that have been co-cultured with either C166 or S17 as above, were harvested with trypsin/EDTA as above. The cells were resuspended in medium containing DMEM supplemented with 10% FBS at a concentration of approximately 1 x 10 4 - 1 x 10 5 .
- Cytospin preparations of these cells were then made by spinning 1 x 10 3 - lx 10" cells onto a glass slide (Superfrost/plus, Fisher) with a Cytospin II centrifuge (Shanndon) . These slides were then fixed with cold acetone and stored frozen at -20°C. For IHC staining the slides were thawed at room temperature and the cell pellet was outlined with a wax pen (DAKO) . The cells were then stained as follows using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA) , all incubations were at room temperature. 100-200 ul PBS was added onto the cells for 5 minutes then removed.
- Vectastain ABC kit Vector Laboratories, Burlingame, CA
- Vectastain blocking antibody solution (horse serum) was then added onto the cells for 15 minutes. The cells were then blotted dry and 100-200 ul of primary antibody solution was added.
- the primary antibodies were: IgGl (1 ug/sample, Sigma), anti-CD34 (0.5 ug/sample, Immunotech) , anti-CD45 (1 ug/sample, DAKO), anti-class I (1 ug/sample, gift from Dr. Paul Leibson, Mayo Clinic), anti-CD14 (1 ug/sample, Pharmingen) , anti-CD31 (1 ug/sample, Pharmingen) .
- CD34 + was demonstrated within a mixed population of cells (about 1%) after 2-3 weeks. Even more importantly, differentiated ES cells were shown to develop into hematopoietic colonies when harvested, separated into cells and plated into methylcellulose (semi-solid) cultures .
- hematopoietic cell transplantation is conducted clinically primarily for patients who have received high dose chemotherapy for treatment of malignancies. These patients typically receive a heterogeneous mixture of hematopoietic cells either from an autologous or allogeneic source. Human ES-derived hematopoietic stem cells will at minimum provide a more homogeneous cell population for hematopoietic cell transplantation.
- both hematopoietic stem cells (HSCs) and a second lineage could be derived from the same parental ES cell line.
- HSCs hematopoietic stem cells
- a second lineage e.g. pancreatic islets for diabetes or oligodendrocytes for multiple sclerosis
- HCT fully allogeneic hematopoietic cell transplant
- oligodendrocytes have been obtained from mouse ES cells (0. Housele et al . , 285 Science 754-6 (1999)), as have cardiac muscle cells (M. Klug et al.. 98 J. Clin. Invest. 216-224 (1996)).
- This method of creating hematopoietic chimeras will also promote acceptance of tissues transplanted for reasons other than autoimmunity .
- mice receiving allogeneic hematopoietic stem cells do not reject other tissues with the same genetic background as the hematopoietic cells, but will still reject third- party grafts. See K. Gandy et al . , 65 Transplantation 295-304 (1998) .
- kidney transplant In addition to animal studies, there are now clinical case reports of human patients who have previously received a hematopoietic cell transplant later requiring a solid organ (kidney) transplant. In these instances, the kidney transplant from the same person who had previously supplied the bone marrow transplant is immunologically accepted without further immunosuppression. See T. Spitzer et . al . , 68 Transplantation 480-484 (1999) .
- the invention provides blood-related cells useful for transplantation, research and other purposes.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU69404/00A AU784928B2 (en) | 1999-11-08 | 2000-08-25 | Hematopoietic differentiation of human embryonic stem cells |
IL14938700A IL149387A0 (en) | 1999-11-08 | 2000-08-25 | Hematopoietic differentiation of human embryonic stem cells |
EP00957842A EP1228194A1 (en) | 1999-11-08 | 2000-08-25 | Hematopoietic differentiation of human embryonic stem cells |
BR0015374-5A BR0015374A (en) | 1999-11-08 | 2000-08-25 | Hematopoietic differentiation of human embryonic stem cells |
CA002390281A CA2390281C (en) | 1999-11-08 | 2000-08-25 | Hematopoietic differentiation of human embryonic stem cells |
JP2001537473A JP2003513664A (en) | 1999-11-08 | 2000-08-25 | Hematopoietic differentiation of human embryonic stem cells |
IL149387A IL149387A (en) | 1999-11-08 | 2002-04-28 | Hematopoietic differentiation of human embryonic stem cells |
SE0201328A SE526490C2 (en) | 1999-11-08 | 2002-05-03 | Hematopoietic differentiation of human embryonic stem cells |
IS6373A IS6373A (en) | 1999-11-08 | 2002-05-06 | Human fetal cells, specialized in haematopoietic cells |
NO20022180A NO20022180L (en) | 1999-11-08 | 2002-05-07 | Hematopoietic differentiation of human embryonic stem cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/435,578 US6280718B1 (en) | 1999-11-08 | 1999-11-08 | Hematopoietic differentiation of human pluripotent embryonic stem cells |
US09/435,578 | 1999-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001034776A1 true WO2001034776A1 (en) | 2001-05-17 |
Family
ID=23728955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/023469 WO2001034776A1 (en) | 1999-11-08 | 2000-08-25 | Hematopoietic differentiation of human embryonic stem cells |
Country Status (13)
Country | Link |
---|---|
US (3) | US6280718B1 (en) |
EP (1) | EP1228194A1 (en) |
JP (3) | JP2003513664A (en) |
KR (2) | KR20030022766A (en) |
CN (1) | CN1228443C (en) |
AU (1) | AU784928B2 (en) |
BR (1) | BR0015374A (en) |
CA (1) | CA2390281C (en) |
IL (2) | IL149387A0 (en) |
IS (1) | IS6373A (en) |
NO (1) | NO20022180L (en) |
SE (1) | SE526490C2 (en) |
WO (1) | WO2001034776A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6759244B2 (en) | 2001-11-08 | 2004-07-06 | Art Institute Of New York And New Jersey, Inc. | Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos |
EP1463803A2 (en) * | 2001-12-07 | 2004-10-06 | Geron Corporation | Hematopoietic cells from human embryonic stem cells |
JP2004535820A (en) * | 2001-07-24 | 2004-12-02 | イーエス・セル・インターナショナル・プロプライエタリー・リミテッド | Methods for inducing stem cell differentiation |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
WO2006050330A2 (en) * | 2004-11-01 | 2006-05-11 | Wisconsin Alumni Research Foundation | Platelets from stem cells |
EP1904624A1 (en) * | 2005-07-20 | 2008-04-02 | Seoul National University Industry Foundation | Method for culturingand proliferating hematopoietic stem cells and progenitor cells using human endometrial cells |
WO2010098079A1 (en) | 2009-02-24 | 2010-09-02 | 学校法人金沢医科大学 | Method for denucleating nucleated erythrocyte, and denucleation inducer |
US7799324B2 (en) | 2001-12-07 | 2010-09-21 | Geron Corporation | Using undifferentiated embryonic stem cells to control the immune system |
US7838289B2 (en) | 2001-02-14 | 2010-11-23 | Abt Holding Company | Assay utilizing multipotent adult stem cells |
US8048999B2 (en) | 2005-12-13 | 2011-11-01 | Kyoto University | Nuclear reprogramming factor |
US8058065B2 (en) | 2005-12-13 | 2011-11-15 | Kyoto University | Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells |
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
US8211697B2 (en) | 2007-06-15 | 2012-07-03 | Kyoto University | Induced pluripotent stem cells produced using reprogramming factors and a rho kinase inhibitor or a histone deacetylase inhibitor |
US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
US8791248B2 (en) | 2007-12-10 | 2014-07-29 | Kyoto University | Nuclear reprogramming factor comprising miRNA and a protein factor |
WO2014171486A1 (en) | 2013-04-17 | 2014-10-23 | 日産化学工業株式会社 | Medium composition and method for producing red blood cells using same |
US9005964B2 (en) | 2006-11-24 | 2015-04-14 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
AU2012258384B2 (en) * | 2001-12-07 | 2016-04-21 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
US9499797B2 (en) | 2008-05-02 | 2016-11-22 | Kyoto University | Method of making induced pluripotent stem cells |
US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
AU2016206280B2 (en) * | 2001-12-07 | 2018-05-17 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
Families Citing this family (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
JP2002529070A (en) * | 1998-11-09 | 2002-09-10 | モナシュ・ユニヴァーシティ | Embryonic stem cells |
US20030129745A1 (en) * | 1999-10-28 | 2003-07-10 | Robl James M. | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
US6280718B1 (en) * | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
US6602711B1 (en) * | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
US6534052B1 (en) | 2000-09-05 | 2003-03-18 | Yong-Fu Xiao | Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated |
US6607720B1 (en) | 2000-09-05 | 2003-08-19 | Yong-Fu Xiao | Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction |
AU2002220209B2 (en) | 2000-12-06 | 2006-05-25 | Robert J. Hariri | Method of collecting placental stem cells |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
US20030032179A1 (en) * | 2000-12-06 | 2003-02-13 | Hariri Robert J. | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP1366148A2 (en) * | 2001-01-24 | 2003-12-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Differentiation of stem cells to pancreatic endocrine cells |
US20030211605A1 (en) * | 2001-05-01 | 2003-11-13 | Lee Sang-Hun | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
MXPA04001725A (en) * | 2001-08-24 | 2005-04-11 | Advanced Cell Tech Inc | Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy. |
DE10144326B4 (en) * | 2001-09-10 | 2005-09-22 | Siemens Ag | Method and system for monitoring a tire air pressure |
KR20050044395A (en) * | 2001-11-09 | 2005-05-12 | 아르테셀 사이언스, 인크. | Methods and compositions for the use of stromal cells to support embryonic and adult stem cells |
US20040224403A1 (en) * | 2001-12-07 | 2004-11-11 | Robarts Research Institute | Reconstituting hematopoietic cell function using human embryonic stem cells |
CA2473909A1 (en) * | 2002-01-15 | 2003-07-24 | Advanced Cell Technology, Inc. | Cloning b and t lymphocytes |
US20050170506A1 (en) * | 2002-01-16 | 2005-08-04 | Primegen Biotech Llc | Therapeutic reprogramming, hybrid stem cells and maturation |
US20030134422A1 (en) * | 2002-01-16 | 2003-07-17 | Sayre Chauncey Bigelow | Stem cell maturation for all tissue lines |
US20050090004A1 (en) * | 2003-01-16 | 2005-04-28 | Sayre Chauncey B. | Stem cell maturation for all tissue lines |
US20040076617A1 (en) * | 2002-03-18 | 2004-04-22 | Lieber Jonathan Gregory | Method for production of neutrophils and uses therefor |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
GB0210741D0 (en) * | 2002-05-10 | 2002-06-19 | Medical Res Council | Methods of therapy |
US20040091936A1 (en) * | 2002-05-24 | 2004-05-13 | Michael West | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank |
EP1513928B1 (en) | 2002-05-24 | 2019-08-21 | Advanced Cell Technology, Inc. | A bank of stem cells for producing cells for transplantation having hla antigens matching those of transplant recipients, and methods for making and using such a stem cell bank |
JP2005528105A (en) * | 2002-05-30 | 2005-09-22 | セルジーン・コーポレーション | Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative diseases and myelodysplastic syndromes |
WO2004015077A2 (en) * | 2002-08-08 | 2004-02-19 | University Of Georgia Research Foundation, Inc. | Compositions and methods for neural differentiation of embryonic stem cells |
AU2003286442A1 (en) * | 2002-10-16 | 2004-05-04 | Advanced Cell Technology, Inc. | Methods using gene trapped stem cells for marking pathways of stem cell differentiation and making and isolating differentiated cells |
GB0224415D0 (en) * | 2002-10-21 | 2002-11-27 | Medical Res Council | Compositions |
KR101042448B1 (en) | 2002-11-26 | 2011-06-16 | 안트로제네시스 코포레이션 | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
AU2003302702B2 (en) * | 2002-12-05 | 2008-08-07 | Technion Research & Development Foundation Ltd. | Cultured human pancreatic islets, and uses thereof |
US20040110286A1 (en) * | 2002-12-06 | 2004-06-10 | The John P. Robarts Research Institute | Method for making hematopoietic cells |
NZ566132A (en) * | 2003-02-13 | 2009-09-25 | Anthrogenesis Corp | Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes |
US20060177929A1 (en) * | 2003-03-24 | 2006-08-10 | Klug Christopher A | Regulation of self-renewal in stem cells |
CA2520023C (en) | 2003-04-08 | 2013-02-05 | Yeda Research And Development Co. Ltd | Stem cells having increased sensitivity to sdf-1 and methods of generating and using same |
FR2853551B1 (en) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | STABILIZING FORMULATION FOR IMMUNOGLOBULIN G COMPOSITIONS IN LIQUID FORM AND LYOPHILIZED FORM |
WO2004104166A2 (en) * | 2003-05-07 | 2004-12-02 | La Jolla Institute For Molecular Medicine | Administration of hyaluronic acid to enhance the function of transplanted stem cells |
AU2004281309A1 (en) * | 2003-10-16 | 2005-04-28 | The University Court Of The University Of Edinburgh | Control of ES cell self-renewal and lineage specification, and medium therefor |
IL158868A0 (en) * | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
WO2005049812A1 (en) * | 2003-11-19 | 2005-06-02 | Australian Stem Cell Centre Limited | Methods for producing blood products from pluripotent cells in cell culture |
WO2005056755A2 (en) * | 2003-12-02 | 2005-06-23 | Catholic Healthcare West | Compositions and methods for propagation of neural progenitor cells |
US20070269412A1 (en) | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
WO2005080551A2 (en) * | 2004-02-12 | 2005-09-01 | University Of Newcastle Upon Tyne | Stem cells |
US20050232905A1 (en) * | 2004-03-26 | 2005-10-20 | Yeh Edward T | Use of peripheral blood cells for cardiac regeneration |
EP1735429A4 (en) * | 2004-03-31 | 2008-06-11 | Newlink Genetics Corp | Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof |
US7622108B2 (en) * | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
CA2563518C (en) * | 2004-04-23 | 2014-09-02 | Bioe, Inc. | Multi-lineage progenitor cells |
EP1745125A1 (en) | 2004-05-14 | 2007-01-24 | Becton, Dickinson and Company | Cell culture environments for the serum-free expansion of mesenchymal stem cells |
AU2005271723B2 (en) | 2004-07-13 | 2010-12-16 | Asterias Biotherapeutics, Inc. | Medium for growing human embryonic stem cells |
CA2504451A1 (en) * | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
WO2006040763A2 (en) * | 2004-10-12 | 2006-04-20 | Technion Research & Development Foundation Ltd. | Isolated primate embryonic cells and methods of generating and using same |
US20070077654A1 (en) * | 2004-11-01 | 2007-04-05 | Thomson James A | Platelets from stem cells |
WO2006073966A1 (en) * | 2004-12-30 | 2006-07-13 | Stemlifeline, Inc. | Methods and systems relating to embryonic stem cell lines |
US20060275899A1 (en) * | 2004-12-30 | 2006-12-07 | Stemlifeline, Inc. | Methods and compositions relating to embryonic stem cell lines |
WO2006086746A2 (en) * | 2005-02-09 | 2006-08-17 | Burnham Institute For Medical Research | Homogeneous neural precursor cells |
US8071367B2 (en) | 2005-05-04 | 2011-12-06 | Commonwealth Scientific And Industrial Research Organisation | Selecting, culturing and creating lineage committed hematopoietic stem cells |
US8034613B2 (en) | 2005-06-01 | 2011-10-11 | Wisconsin Alumni Research Foundation | Multipotent lymphohematopoietic progenitor cells |
KR20080015033A (en) | 2005-06-01 | 2008-02-15 | 위스콘신 얼럼나이 리서어치 화운데이션 | Method of forming dendritic cells from embryonic stem cells |
WO2007002086A2 (en) * | 2005-06-22 | 2007-01-04 | Geron Corporation | Suspension culture of human embryonic stem cells |
WO2007002136A2 (en) | 2005-06-22 | 2007-01-04 | Geron Corporation | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells |
ES2452595T3 (en) | 2005-10-13 | 2014-04-02 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
AU2006332679A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
KR20210122908A (en) | 2005-12-29 | 2021-10-12 | 안트로제네시스 코포레이션 | Placental stem cell populations |
WO2007121443A2 (en) * | 2006-04-17 | 2007-10-25 | Bioe, Inc. | Differentiation of multi-lineage progenitor cells to respiratory epithelial cells |
EP2064319B1 (en) | 2006-08-28 | 2017-02-22 | Yeda Research and Development Co. Ltd. | Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns |
US20080108044A1 (en) * | 2006-11-08 | 2008-05-08 | Deepika Rajesh | In vitro differentiation of hematopoietic cells from primate embryonic stem cells |
US7883698B2 (en) * | 2007-01-17 | 2011-02-08 | Maria Michejda | Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use |
DK2120977T3 (en) | 2007-02-12 | 2013-08-12 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
WO2008156708A2 (en) * | 2007-06-15 | 2008-12-24 | Massachusetts Institute Of Technology | Methods and compositions for enhanced differentiation from embryonic stem cells |
CN101835479A (en) * | 2007-07-25 | 2010-09-15 | 佰欧益有限公司 | Differentiation of multi-lineage progenitor cells to chondrocytes |
KR20210022148A (en) | 2007-09-28 | 2021-03-02 | 안트로제네시스 코포레이션 | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
EP3851520A1 (en) | 2008-04-30 | 2021-07-21 | SanBio, Inc. | Neural regenerating cells with alterations in dna methylation |
EP2294187A2 (en) * | 2008-05-21 | 2011-03-16 | BioE LLC | Differentiation of multi-lineage progenitor cells to pancreatic cells |
KR101903049B1 (en) | 2008-08-20 | 2018-11-07 | 안트로제네시스 코포레이션 | Treatment of stroke using isolated placental cells |
KR20110050521A (en) | 2008-08-20 | 2011-05-13 | 안트로제네시스 코포레이션 | Improved cell composition and methods of making the same |
KR20110050688A (en) | 2008-08-22 | 2011-05-16 | 안트로제네시스 코포레이션 | Methods and compositions for treatment of bone defects with placental cell populations |
AU2009316541B2 (en) | 2008-11-19 | 2015-08-06 | Celularity Inc. | Amnion derived adherent cells |
US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
WO2011005326A1 (en) | 2009-07-09 | 2011-01-13 | Massachusetts Institute Of Technology | Methods and compositions for increased safety of stem cell-derived populations |
WO2011017315A2 (en) | 2009-08-03 | 2011-02-10 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
AU2010315712B2 (en) | 2009-10-19 | 2014-04-17 | FUJIFILM Cellular Dynamics, Inc. | Cardiomyocyte production |
EP3284818B1 (en) | 2010-01-26 | 2022-03-09 | Celularity Inc. | Treatment of bone-related cancers using placental stem cells |
KR20230054905A (en) | 2010-04-07 | 2023-04-25 | 셀룰래리티 인코포레이티드 | Angiogenesis using placental stem cells |
WO2011127113A1 (en) | 2010-04-08 | 2011-10-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
WO2011159797A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | A compendium of ready-built stem cell models for interrogation of biological response |
ES2666746T3 (en) | 2010-07-13 | 2018-05-07 | Anthrogenesis Corporation | Methods to generate natural cytolytic lymphocytes |
CA2806858C (en) | 2010-08-04 | 2021-06-15 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
CN103168236B (en) | 2010-08-23 | 2016-01-20 | 哈佛大学管理委员会 | For the light genetics probe that membrane potential measures |
US9725689B2 (en) | 2010-10-08 | 2017-08-08 | Terumo Bct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
CA2814860C (en) | 2010-10-22 | 2020-08-25 | Biotime Inc. | Methods of modifying transcriptional regulatory networks in stem cells |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
EP2801377B1 (en) | 2011-03-04 | 2019-08-07 | The Regents of The University of California | Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke |
US20140329314A1 (en) | 2011-03-29 | 2014-11-06 | Christopher O'Sullivan | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
US8785190B2 (en) | 2011-04-06 | 2014-07-22 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
PL2714059T3 (en) | 2011-06-01 | 2019-04-30 | Celularity Inc | Treatment of pain using placental stem cells |
WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
AU2012298997B2 (en) | 2011-08-23 | 2018-10-04 | Wisconsin Alumni Research Foundation | Angiohematopoietic progenitor cells |
WO2013055476A1 (en) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
EP2594295A1 (en) | 2011-11-16 | 2013-05-22 | Servicio Andaluz De Salud | Nerve implants based on a compacted biomaterial containing cells |
US9447378B2 (en) | 2012-04-27 | 2016-09-20 | Massachusetts Institute Of Technology | Method for differentiating human embryonic stem cells into β-cells for the treatment of type I diabetes |
JP5432322B2 (en) | 2012-05-08 | 2014-03-05 | 株式会社大塚製薬工場 | Mammalian cell suspension for prevention of pulmonary embolism containing trehalose |
AU2013237760A1 (en) | 2012-10-08 | 2014-04-24 | Biotime, Inc. | Differentiated progeny of clonal progenitor cell lines |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
WO2014197421A1 (en) | 2013-06-05 | 2014-12-11 | Biotime, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
WO2014201431A1 (en) | 2013-06-14 | 2014-12-18 | Massachusetts Institute Of Technology | Articles and methods for stem cell differentiation |
WO2014208053A1 (en) | 2013-06-28 | 2014-12-31 | 株式会社大塚製薬工場 | Trehalose and dextran-containing solution for transplanting mammalian cells |
WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
CN103740642A (en) * | 2014-01-28 | 2014-04-23 | 娄彩玲 | Method for preparing human erythrocytes |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
CN106715676A (en) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | Scheduled feed |
EP3868873A1 (en) | 2014-10-24 | 2021-08-25 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for retinal tissue |
US10286009B2 (en) * | 2015-05-16 | 2019-05-14 | Asterias Biotherapeutics, Inc. | Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US11649432B2 (en) | 2015-09-08 | 2023-05-16 | Sumitomo Pharma Co., Ltd. | Method for producing retinal pigment epithelial cells |
EP3387112A4 (en) | 2015-12-07 | 2019-08-21 | BioTime, Inc. | Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells |
EP3423158B1 (en) | 2016-02-24 | 2023-11-15 | The Rockefeller University | Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof |
CN116121189A (en) | 2016-03-30 | 2023-05-16 | 阿斯特利亚斯生物治疗股份公司 | Oligodendrocyte progenitor cell compositions |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11540507B2 (en) | 2016-11-04 | 2023-01-03 | The University Of Tokyo | Solution for cryopreservation of animal cells or animal tissues, cryopreserved product, and cryopreservation method |
AU2017363689B2 (en) | 2016-11-25 | 2023-11-23 | Riken | Cell population for transplantation and method for producing same |
AU2017377309B9 (en) | 2016-12-14 | 2021-06-03 | Otsuka Pharmaceutical Factory, Inc. | Mammalian cell cryopreservation liquid |
US11618883B2 (en) | 2017-03-08 | 2023-04-04 | Sumitomo Pharma Co., Ltd. | Method for producing retinal pigment epithelial cells |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
US11702634B2 (en) | 2017-03-31 | 2023-07-18 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
KR20200029479A (en) | 2017-07-20 | 2020-03-18 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | Methods of preservation of nerve tissue |
EP3656852A4 (en) | 2017-07-20 | 2021-04-21 | Riken | Method for maturation of retinal tissue containing continuous epithelium |
AU2018330694A1 (en) | 2017-09-08 | 2020-03-19 | Riken | Cell aggregate including retinal tissue and production method therefor |
CA3075883A1 (en) | 2017-09-14 | 2019-03-21 | Riken | Method for amplifying cone photoreceptors or rod photoreceptors using dorsalization signal transmitter or ventralization signal transmitter |
WO2019054514A1 (en) | 2017-09-14 | 2019-03-21 | 国立研究開発法人理化学研究所 | Method for producing retinal tissues |
AU2018371437A1 (en) | 2017-11-24 | 2020-07-02 | Sumitomo Chemical Company, Limited | Production method for cell mass including neural cells/tissue and non-neural epithelial tissue, and cell mass from same |
JP7297674B2 (en) | 2017-11-24 | 2023-06-26 | 住友化学株式会社 | Method for producing cell mass containing pituitary tissue and cell mass thereof |
CN111788303A (en) | 2018-02-19 | 2020-10-16 | 大日本住友制药株式会社 | Cell aggregate, mixture of cell aggregates, and method for producing same |
WO2020039732A1 (en) | 2018-08-24 | 2020-02-27 | 住友化学株式会社 | Cell aggregation including olfactory neuron or precursor cell thereof, and method for producing same |
CA3112902A1 (en) | 2018-09-28 | 2020-04-02 | Otsuka Pharmaceutical Factory, Inc. | Mammal cell preserving solution containing acarbose or stachyose |
US20220010271A1 (en) | 2018-11-15 | 2022-01-13 | Jsr Corporation | Method for producing brain organoids |
EP3901253A4 (en) | 2018-12-20 | 2022-09-07 | Sumitomo Chemical Company Limited | Embryonic erythroblast-containing cell population and method for producing same, cell culture composition, and compound test method |
EP3903789A4 (en) | 2018-12-28 | 2022-10-05 | Riken | Therapeutic drug for disease accompanied by disorders in retinal system cells or retinal tissue |
AU2020210757A1 (en) | 2019-01-23 | 2021-08-05 | Asterias Biotherapeutics, Inc. | Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells |
CA3132804A1 (en) | 2019-03-13 | 2020-09-17 | Sumitomo Dainippon Pharma Co., Ltd. | Method for evaluating quality of transplant neural retina, and transplant neural retina sheet |
AU2020260894A1 (en) | 2019-04-26 | 2021-11-18 | Riken | Composite including neural retina, retinal pigment epithelial cells, and hydrogel, and method for producing same |
AU2020263769B2 (en) | 2019-04-26 | 2023-07-06 | Otsuka Pharmaceutical Factory, Inc. | Trehalose-containing liquid for mammalian cell preservation |
KR20220052946A (en) | 2019-09-06 | 2022-04-28 | 각고호우징 게이오기주크 | Method for producing cell aggregates containing glial progenitor cells |
EP4063495A4 (en) | 2019-11-20 | 2023-12-27 | Sumitomo Pharma Co., Ltd. | Method for freezing cell aggregates |
EP4063496A1 (en) | 2019-11-20 | 2022-09-28 | Sumitomo Pharma Co., Ltd. | Method for freezing neural cells |
CA3194364A1 (en) | 2020-09-11 | 2022-03-17 | Sumitomo Pharma Co., Ltd. | Medium for tissue for transplantation |
CN116157512A (en) | 2020-09-11 | 2023-05-23 | 国立研究开发法人理化学研究所 | Composite comprising cell aggregate containing neural retina and matrix, and method for producing same |
JPWO2022191216A1 (en) | 2021-03-09 | 2022-09-15 | ||
WO2022265086A1 (en) | 2021-06-17 | 2022-12-22 | 国立大学法人京都大学 | Method for producing cerebral cortical cell preparation derived from human pluripotent stem cells |
WO2023039588A1 (en) | 2021-09-13 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
WO2023049826A1 (en) | 2021-09-23 | 2023-03-30 | President And Fellows Of Harvard College | Genetically encoded voltage indicators and uses thereof |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998007841A1 (en) * | 1996-08-19 | 1998-02-26 | University Of Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
US5914268A (en) * | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635386A (en) * | 1989-06-15 | 1997-06-03 | The Regents Of The University Of Michigan | Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture |
NZ314644A (en) * | 1993-05-24 | 2000-11-24 | Immunex Corp | Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US6280718B1 (en) * | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
-
1999
- 1999-11-08 US US09/435,578 patent/US6280718B1/en not_active Expired - Lifetime
-
2000
- 2000-08-25 EP EP00957842A patent/EP1228194A1/en not_active Withdrawn
- 2000-08-25 JP JP2001537473A patent/JP2003513664A/en active Pending
- 2000-08-25 WO PCT/US2000/023469 patent/WO2001034776A1/en active IP Right Grant
- 2000-08-25 IL IL14938700A patent/IL149387A0/en active IP Right Grant
- 2000-08-25 BR BR0015374-5A patent/BR0015374A/en not_active Application Discontinuation
- 2000-08-25 CA CA002390281A patent/CA2390281C/en not_active Expired - Lifetime
- 2000-08-25 KR KR1020027005890A patent/KR20030022766A/en not_active Application Discontinuation
- 2000-08-25 CN CNB008153264A patent/CN1228443C/en not_active Expired - Lifetime
- 2000-08-25 KR KR1020077008013A patent/KR20070047850A/en active Search and Examination
- 2000-08-25 AU AU69404/00A patent/AU784928B2/en not_active Expired
-
2001
- 2001-08-27 US US09/940,175 patent/US6613568B2/en not_active Expired - Lifetime
-
2002
- 2002-04-28 IL IL149387A patent/IL149387A/en unknown
- 2002-05-03 SE SE0201328A patent/SE526490C2/en unknown
- 2002-05-06 IS IS6373A patent/IS6373A/en unknown
- 2002-05-07 NO NO20022180A patent/NO20022180L/en not_active Application Discontinuation
-
2003
- 2003-08-29 US US10/652,468 patent/US20040043484A1/en not_active Abandoned
-
2009
- 2009-10-01 JP JP2009229464A patent/JP2010042011A/en active Pending
-
2013
- 2013-10-07 JP JP2013210318A patent/JP2014000096A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914268A (en) * | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
WO1998007841A1 (en) * | 1996-08-19 | 1998-02-26 | University Of Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
Non-Patent Citations (9)
Title |
---|
C. BAUM ET AL., PNAS USA, vol. 89, 1992, pages 2804 - 2808 |
COLLINS L S ET AL: "A STROMAL CELL LINE FROM MYELOID LONG-TERM BONE MARROW CULTURES CAN SUPPORT MYELOPOIESIS AND B LYMPHOPOIESIS", JOURNAL OF IMMUNOLOGY, vol. 138, no. 4, 1987, pages 1082 - 1087, XP000944690, ISSN: 0022-1767 * |
KAUFMAN DAN S ET AL: "Directed differentiation of human embryonic stem cells into hematopoietic colony forming cells.", BLOOD, vol. 94, no. 10 SUPPL. 1 PART 1, 15 November 1999 (1999-11-15), Forty-first Annual Meeting of the American Society of Hematology;New Orleans, Louisiana, USA; December 3-7, 1999, pages 34a, XP000942815, ISSN: 0006-4971 * |
KELLER G M: "IN VITRO DIFFERENTIATION OF EMBRYONIC STEM CELLS", CURRENT OPINION IN CELL BIOLOGY, vol. 7, 1995, pages 862 - 869, XP002912250, ISSN: 0955-0674 * |
LI FEI ET AL: "Hematopoietic differentiation in vitro of rhesus monkey embryonic stem cells.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), 40th Annual Meeting of the American Society of Hematology;Miami Beach, Florida, USA; December 4-8, 1998, pages 368A, XP000944686, ISSN: 0006-4971 * |
LU LI-SHENG ET AL: "In vitro and in vivo differentiation into B cells, T cells, and myeloid cells of primitive yolk sac hematopoietic precursor cells expanded greater than 100-fold by coculture with a clonal yolk sac endothelial cell line.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 25, 1996, 1996, pages 14782 - 14787, XP000941667, ISSN: 0027-8424 * |
RATHJEN P D ET AL: "PROPERTIES AND USES OF EMBRYONIC STEM CELLS: PROSPECTS FOR APPLICATION TO HUMAN BIOLOGY AND GENE THERAPY", REPRODUCTION, FERTILITY AND DEVELOPMENT, vol. 10, no. 1, 1998, pages 31 - 47, XP000916997, ISSN: 1031-3613 * |
S. MORRISON ET AL., ANNU. REV. CELL DEV. BIOL., vol. 11, 1995, pages 35 - 71 |
THOMSON JAMES A ET AL: "Embryonic stem cell lines derived from human blastocytes.", SCIENCE, vol. 282, no. 5391, 6 November 1998 (1998-11-06), pages 1145 - 1147, XP002121340, ISSN: 0036-8075 * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7659118B2 (en) | 1999-08-05 | 2010-02-09 | Abt Holding Company | Multipotent adult stem cells |
US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
US10226485B2 (en) | 1999-08-05 | 2019-03-12 | Abt Holding Company | Multipotent adult stem cells and methods for isolation |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US7838289B2 (en) | 2001-02-14 | 2010-11-23 | Abt Holding Company | Assay utilizing multipotent adult stem cells |
JP2004535820A (en) * | 2001-07-24 | 2004-12-02 | イーエス・セル・インターナショナル・プロプライエタリー・リミテッド | Methods for inducing stem cell differentiation |
US8728457B2 (en) | 2001-07-24 | 2014-05-20 | Christine Lindsay Mummery | Methods of inducing differentiation of stem cells |
US6759244B2 (en) | 2001-11-08 | 2004-07-06 | Art Institute Of New York And New Jersey, Inc. | Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos |
AU2016206280B2 (en) * | 2001-12-07 | 2018-05-17 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
US7799324B2 (en) | 2001-12-07 | 2010-09-21 | Geron Corporation | Using undifferentiated embryonic stem cells to control the immune system |
KR101457742B1 (en) * | 2001-12-07 | 2014-11-03 | 아스테리아스 바이오세라퓨틱스, 인크. | Hematopoietic cells from human embryonic stem cells |
EP1463803A2 (en) * | 2001-12-07 | 2004-10-06 | Geron Corporation | Hematopoietic cells from human embryonic stem cells |
EP2292734A1 (en) * | 2001-12-07 | 2011-03-09 | Geron Corporation | Hematopoietic cells from human embryonic stem cells |
AU2012258384B2 (en) * | 2001-12-07 | 2016-04-21 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
EP1463803A4 (en) * | 2001-12-07 | 2005-02-02 | Geron Corp | Hematopoietic cells from human embryonic stem cells |
JP2005511084A (en) * | 2001-12-07 | 2005-04-28 | ジェロン コーポレイション | Hematopoietic cells derived from human embryonic stem cells |
CN102008503A (en) * | 2001-12-07 | 2011-04-13 | 杰龙公司 | Hematopoietic cells from human embryonic stem cells |
US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
WO2006050330A3 (en) * | 2004-11-01 | 2006-08-24 | Wisconsin Alumni Res Found | Platelets from stem cells |
WO2006050330A2 (en) * | 2004-11-01 | 2006-05-11 | Wisconsin Alumni Research Foundation | Platelets from stem cells |
GB2434157A (en) * | 2004-11-01 | 2007-07-18 | Wisconsin Alumni Re Foundation | Platelets from stem cells |
JP2008518603A (en) * | 2004-11-01 | 2008-06-05 | ウイスコンシン アラムニ リサーチ ファンデーション | Stem cell-derived platelets |
EP1904624A1 (en) * | 2005-07-20 | 2008-04-02 | Seoul National University Industry Foundation | Method for culturingand proliferating hematopoietic stem cells and progenitor cells using human endometrial cells |
EP1904624A4 (en) * | 2005-07-20 | 2010-01-06 | Seoul Nat Univ Ind Foundation | Method for culturing and proliferating hematopoietic stem cells and progenitor cells using human endometrial cells |
US8048999B2 (en) | 2005-12-13 | 2011-11-01 | Kyoto University | Nuclear reprogramming factor |
US8058065B2 (en) | 2005-12-13 | 2011-11-15 | Kyoto University | Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells |
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
US9005964B2 (en) | 2006-11-24 | 2015-04-14 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
US8211697B2 (en) | 2007-06-15 | 2012-07-03 | Kyoto University | Induced pluripotent stem cells produced using reprogramming factors and a rho kinase inhibitor or a histone deacetylase inhibitor |
US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
US8257941B2 (en) | 2007-06-15 | 2012-09-04 | Kyoto University | Methods and platforms for drug discovery using induced pluripotent stem cells |
US9714433B2 (en) | 2007-06-15 | 2017-07-25 | Kyoto University | Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue |
US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
US8791248B2 (en) | 2007-12-10 | 2014-07-29 | Kyoto University | Nuclear reprogramming factor comprising miRNA and a protein factor |
US9499797B2 (en) | 2008-05-02 | 2016-11-22 | Kyoto University | Method of making induced pluripotent stem cells |
WO2010098079A1 (en) | 2009-02-24 | 2010-09-02 | 学校法人金沢医科大学 | Method for denucleating nucleated erythrocyte, and denucleation inducer |
WO2014171486A1 (en) | 2013-04-17 | 2014-10-23 | 日産化学工業株式会社 | Medium composition and method for producing red blood cells using same |
Also Published As
Publication number | Publication date |
---|---|
NO20022180L (en) | 2002-06-03 |
AU784928B2 (en) | 2006-07-27 |
JP2014000096A (en) | 2014-01-09 |
US20040043484A1 (en) | 2004-03-04 |
KR20070047850A (en) | 2007-05-07 |
CN1228443C (en) | 2005-11-23 |
US6613568B2 (en) | 2003-09-02 |
CA2390281C (en) | 2005-10-25 |
SE0201328D0 (en) | 2002-05-03 |
CA2390281A1 (en) | 2001-05-17 |
BR0015374A (en) | 2002-12-24 |
IL149387A0 (en) | 2002-11-10 |
JP2010042011A (en) | 2010-02-25 |
SE0201328L (en) | 2002-07-05 |
US6280718B1 (en) | 2001-08-28 |
AU6940400A (en) | 2001-06-06 |
KR20030022766A (en) | 2003-03-17 |
NO20022180D0 (en) | 2002-05-07 |
IS6373A (en) | 2002-05-06 |
SE526490C2 (en) | 2005-09-27 |
JP2003513664A (en) | 2003-04-15 |
IL149387A (en) | 2008-08-07 |
EP1228194A1 (en) | 2002-08-07 |
US20020015694A1 (en) | 2002-02-07 |
CN1387565A (en) | 2002-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6280718B1 (en) | Hematopoietic differentiation of human pluripotent embryonic stem cells | |
US11261426B2 (en) | Pluripotent stem cell that can be isolated from body tissue | |
US20030153082A1 (en) | Hematopoietic cells from human embryonic stem cells | |
US20210395684A1 (en) | Methods and systems for manufacturing hematopoietic lineage cells | |
US20050221482A1 (en) | Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof | |
JP2021535747A (en) | Generation of hematopoietic progenitor cells from human pluripotent stem cells | |
JPWO2008056779A1 (en) | Method for culturing and subculture of primate embryonic stem cells and method for inducing differentiation thereof | |
JP2005512592A (en) | Cellular composition, method for producing cellular composition, and method of using cellular composition | |
US20040110286A1 (en) | Method for making hematopoietic cells | |
Gordon-Keylock et al. | Induction of hematopoietic differentiation of mouse embryonic stem cells by an AGM-derived stromal cell line is not further enhanced by overexpression of HOXB4 | |
CN113557296A (en) | Expansion of hematopoietic stem cells | |
US20230374458A1 (en) | Compositions and methods for generating human yolk sac-like hematopoietic cells | |
Bhatia | The ultimate source of human hematopoietic stem cells: thinking outside the marrow | |
Kaufman et al. | Embryonic Stem Cells: Unique Potential to Treat Autoimmune Diseases | |
Kelley et al. | Collection and Expansion of Stem Cells | |
Kaufman et al. | Embryonicmaintainedlines, of yet human retain stem indefinitely embryonic (ES) their cells ability in are stem culture pluripotent to cells form as provides undifferentiated any cells cell a that new type. can model The cell | |
EP3564363A1 (en) | Production of megakaryocytes in bioreactors | |
AU2016206280A1 (en) | Hematopoietic cells from human embryonic stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 149387 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/548/KOL Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 518683 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2390281 Country of ref document: CA Ref document number: 02013282 Country of ref document: SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027005890 Country of ref document: KR Ref document number: PA/a/2002/004551 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2001 537473 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008153264 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 69404/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000957842 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 02013282 Country of ref document: SE |
|
WWP | Wipo information: published in national office |
Ref document number: 2000957842 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027005890 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 518683 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 518683 Country of ref document: NZ |